LY4006895 Clinical Trials (2026): 1 Studies for Alzheimer Disease & Healthy
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
1 LY4006895 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 1 indication (including Alzheimer Disease & Healthy) and 128 total planned enrollment. 1 LY4006895 clinical trial is actively recruiting at 6 U.S. sites across 4 states. Most recent activity: NCT06657768 (Jul 2027).
Where to Participate: All LY4006895 Trial Sites in the U.S. (6 sites across 4 states)
Every actively recruiting LY4006895trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| CA | Collaborative Neuroscience Network - CNS | Los Alamitos90720 | NCT06657768 | Map |
| FL | K2 Medical Research - The Villages | Lady Lake32159 | NCT06657768 | Map |
| FL | K2 Medical Research | Maitland32751 | NCT06657768 | Map |
| GA | Atlanta Center of Medical Research | Atlanta30331 | NCT06657768 | Map |
| GA | CenExel iResearch, LLC (CenExel iRA) | Decatur30030 | NCT06657768 | Map |
| NJ | CenExel-HRI | Marlton08053 | NCT06657768 | Map |
LY4006895 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | Total |
|---|---|---|
| P1 | 1 | 1 |
Recruiting LY4006895 clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT06657768 | ADA Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD) | P1 | Alzheimer Disease | 128 | Oct 2024 |
All LY4006895 trials (1)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT06657768 | AD | A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD) | P1 | recruiting | 128 | Eli Lilly and Company | Oct 2024 |
LY4006895 clinical trials: frequently asked questions
- How many LY4006895 clinical trials are there?
- 1 LY4006895 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants.
- Are LY4006895 clinical trials recruiting in 2026?
- Yes — 1 LY4006895 trial is actively recruiting in 2026, with 6 U.S. sites across 4 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is LY4006895 being studied for?
- LY4006895 is being studied for Alzheimer Disease, Healthy. The trials are grouped by indication on this page.
- What phase is LY4006895 in?
- LY4006895 clinical trials span 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors LY4006895 clinical trials?
- The lead sponsor across the most LY4006895 trials is Eli Lilly and Company. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming LY4006895as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: